BioMarin resolves patent infringement claims against Par Pharmaceutical related to Kuvan®
Clients BioMarin Pharmaceutical Inc.
Jones Day client BioMarin Pharmaceutical, Inc. successfully resolved a patent infringement action against Par Pharmaceutical, Inc. relating to the defendant's submission of an Abbreviated New Drug Application to the FDA seeking approval of a generic version of Kuvan® (sapropterin dihydrocholride), the only FDA-approved treatment to reduce blood phenylalanine levels in persons with BH-4 responsive phenylketonuria (PKU).
BioMarin Pharmaceutical Inc. et al. v. Par Pharmaceutical, Inc., Case No. 3:15-cv-01706 (D.N.J.)